- Home
- RUM vs IMNM Comparison
RUM vs IMNM Comparison
Compare RUM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | IMNM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RUM | IMNM |
|---|---|---|
| Price | $6.41 | $22.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $15.00 | ★ $26.89 |
| AVG Volume (30 Days) | ★ 3.4M | 1.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,782,153.00 | $9,679,000.00 |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $81.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.17 | N/A |
| 52 Week Low | $5.11 | $5.15 |
| 52 Week High | $17.40 | $20.80 |
Technical Indicators
Market Signals| Indicator | RUM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 68.39 |
| Support Level | $6.97 | $18.81 |
| Resistance Level | $7.62 | $20.80 |
| Average True Range (ATR) | 0.40 | 1.45 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 6.60 | 64.90 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.